Changes in Cerebrospinal Fluid Biomarkers in Human Herpesvirus-6-Associated Acute Encephalopathy/Febrile Seizures

Table 4

Clinical profile of patients receiving edaravone treatment.

Patient	Clinical diagnosis	Age/sex	Initiation and dosage of edaravone treatment	Other treatments	Outcomes
1	HHV-6 encephalopathy	14 m/M	Day 5; 0.5 mg/kg × 2/day × 7 days	Mannitol, Dexamethasone,; Ganciclovir,; MDL, PHT	Intellectual disability
2	HHV-6 encephalopathy; (AESD)	12 m/F	Day 5; 0.5 mg/kg × 2/day × 8 days	Mannitol, Dexamethasone,; Ganciclovir,; DZP, MDL	Without sequelae
3	HHV-6 encephalopathy	14 m/M	Day 4; 0.5 mg/kg × 2/day × 10 days	Mannitol, Dexamethasone,; Ganciclovir/acyclovir,; DZP, MDL	Hemophagocytic syndrome; Died of fulminant hepatitis
4	HHV-6 encephalopathy; (AESD)	20 m/F	Day 7; 0.5 mg/kg × 2/day × 7 days	Mannitol, Dexamethasone,; Aciclovir,; MDL	Lt hemiparesis
5	HHV-6 encephalopathy; (AESD)	12 m/M	Day 3; 15 mg/day × 10 days	DZP, MDL,; steroid pulse therapy,; mild therapeutic hypothermia	Moderate psychomotor retardation
6	HHV-6 febrile seizures	10 m/F	Day 1; 0.5 mg/kg × 2/day × 12 days	Mannitol, Dexamethasone,; Ganciclovir/acyclovir,; DZP, MDL, PHT	Without sequelae

m: months; M: male; F: female; DZP: diazepam; MDL: midazolam; PHT: phenytoin; Lt: left; HHV: human herpesvirus; AESD: acute encephalopathy with biphasic seizures and late reduced diffusion.